Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Inclusion Criteria:

Initial Screening

* Radiologically confirmed DIPG or other diffuse intrinsic brain stem glioma (Grade III or IV).
* Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor material for confirmatory diagnosis and/or tumor RNA extraction and amplification.
* Biopsy confirmation of any grade of glioma (for patients with classic DIPG on neuroimaging or at least grade III glioma in case of other diffuse intrinsic brain stem gliomas)
* Karnofsky Performance Status (KPS) of \> 50% (KPS for \> 16 years of age) or Lansky performance Score (LPS) of ≥ 50 (LPS for ≤ 16 years of age) assessed within 2 weeks prior to registration;
* Bone Marrow;
* ANC (absolute neutrophil count) ≥ 1000/µl (unsupported)
* Platelets ≥ 100,000/µl (unsupported)
* Hemoglobin \> 8 g/dL (can be transfused)
* Renal;
* Serum creatinine ≤ upper limit of institutional normal
* Hepatic;
* Bilirubin ≤ 1.5 times upper limit of institutional normal for age
* SGPT (ALT) ≤ 3 times upper limit of institutional normal for age
* SGOT (AST) ≤ 3 times upper limit of institutional normal for age
* Patients of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control while being treated on this study.
* Signed informed consent according to institutional guidelines.

Post Biopsy

* Patients with post-surgical neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration;
* Pathologic diagnosis of glioma on tumor biopsy.

Exclusion Criteria:

* Patients with severe dysphagia, obtundation, or tetraplegia (poor risks for anesthesia and biopsy procedure);
* Absence of tumor on biopsy specimen;
* Pregnant or need to breast feed during the study period (Negative serum pregnancy test required)
* Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection;
* Patients with significant renal, cardiac, pulmonary, hepatic or other organ dysfunction;
* Severe or unstable concurrent medical conditions;
* Patients who require corticosteroids above physiologic doses (\>4 mg/day dexamethasone) after chemoradiotherapy;
* Patients scheduled to receive any other concurrent anticancer or investigational drug therapy;
* Prior allergic reaction to TMZ, GM-CSF, or Td;
* Patients who are unwilling or unable to receive treatment and undergo follow-up evaluations at University of Florida;
* Patient and/or parent/guardian demonstrating an inability to comply with the study and/or follow-up procedures.